Inactive Instrument

Evotec SE Share Price Other OTC

Equities

EVTCY

US30050E1055

Biotechnology & Medical Research

Financials

Sales 2024 * 875M 947M 78.9B Sales 2025 * 1.03B 1.11B 92.66B Capitalization 1.7B 1.84B 154B
Net income 2024 * -28M -30.33M -2.53B Net income 2025 * 24M 25.99M 2.16B EV / Sales 2024 * 2.25 x
Net Debt 2024 * 269M 291M 24.27B Net Debt 2025 * 235M 255M 21.2B EV / Sales 2025 * 1.89 x
P/E ratio 2024 *
-61.3 x
P/E ratio 2025 *
36.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 19/19/19
Director of Finance/CFO 51 07/23/07
Chief Operating Officer 54 01/12/01
Members of the board TitleAgeSince
Chief Executive Officer 61 19/19/19
Director/Board Member 56 19/19/19
Chairman 63 17/14/17
More insiders
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company